On Nov 13, major Wall Street analysts update their ratings for $Axsome Therapeutics (AXSM.US)$, with price targets ranging from $116 to $150.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and adjusts the target price from $115 to $125.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $106 to $118.
Wells Fargo analyst Cerena Chen maintains with a buy rating, and maintains the target price at $140.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $120 to $125.
Guggenheim analyst Yatin Suneja maintains with a buy rating, and sets the target price at $135.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a third-quarter update, which included surpassing revenue expectations and positive pipeline developments, an analyst has maintained a positive outlook on Axsome Therapeutics. Clarifications regarding the schedule of two concurrent Phase 3 Auvelity ADA trials have delineated the timeline of upcoming catalyst events, with expectations for simultaneous study results in the fourth quarter. It's believed that success in either one of the ADA trials could dispel any lingering concerns over the regulatory outlook for this significant label expansion.
The recent quarter was notably strong for Axsome Therapeutics, chiefly attributed to a promising increase in Auvelity sales. The company remains a top selection due to the belief that its stock possesses the most compelling series of catalysts through the end of the year in the coverage universe.
Here are the latest investment ratings and price targets for $Axsome Therapeutics (AXSM.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
